EPV174/#144 Perioperative blood management of Jehovah’s witnesses undergoing cytoreductive surgery for advanced ovarian cancer

Palaia, Innocenza; Caruso, Giuseppe; Donato, Violante Di; Perniola, Giorgia; Ferrazza, Giancarlo; Panzini, Enrico; Scudo, Maria; Gallo, Roberta; Muzii, Ludovico; Panici, Pierluigi Benedetti

doi:10.1136/ijgc-2021-igcs.245

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanisms associated with PD-1 can affect its expression, and the functionality of toxic T cells will be limited with regards to the control of tumor immunity [12,13]. Karelizumab is a PD-1 inhibitor; after binding to PD-L1 on the surface of T lymphocytes and other cells, karelizumab will reduce mediated immunosuppression, activate more T cells, generate immune checkpoints, and kill tumor cells [14,15]. Karelizumab can prolong a patient's survival time, control the spread and metastasis of tumor cells, and reduce angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of TP chemotherapy combined with karelizumab on the postoperative clinical status of patients with advanced ovarian cancer

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

To investigate the efficacy of TP (Toripalimab Plus) chemotherapy combined with karelizumab in the treatment of advanced ovarian cancer after surgery. We recruited 96 patients with advanced ovarian cancer who were admitted to our hospital between December 2019 and December 2022 with advanced ovarian cancer and treated by tumor cell reduction surgery. The patients were randomly divided into groups using a digital table, 48 each. The control group was treated with chemotherapy, while the observation group was treated with chemotherapy combined with karelizumab. We compared the two groups with regards to adverse reactions and the levels of VEGF (Vascular Endothelial Growth Factor), MMP-9 (matrixmetalloproteinase 9), CEA (A Carcinoma Embryonic Antigen), AFP (alpha-fetoprotein), CA125 (carbohydrate antigen 125), CA19-9 (carbohydrate antigen 19-9) and T lymphocytes. There was no significant difference between the two groups with regards to adverse reactions (p > 0.05); the levels of VEGF and MMP-9 in the observation group were lower. There was a significant difference between the data before and after treatment within the same group (all p < 0.05); the levels of CEA, AFP, CA125 and CA19-9 in the observation group were lower than those in the control group, with significant differences before and after treatment within the same group (p < 0.05); the levels of CD3+ (cluster of differentiation 3+) and CD4+ in the observation group were higher, while the levels of CD8+ were lower than those in the control group. There were significant differences before and after treatment in the same group (p < 0.05). The combination of karelizumab and TP chemotherapy had a significant and positive impact on postoperative patients with advanced ovarian cancer by effectively regulating immune function and the levels of tumor markers. This protocol is safe and can be selected by considering the specific situation of individual patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy of TP chemotherapy combined with karelizumab on the postoperative clinical status of patients with advanced ovarian cancer

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

show abstract

“…Patient blood management services are focused on optimizing patients’ hemoglobin and aim to reduce allogenic blood transfusion 10 , 11 , 12 , 13 , 14 , 15 , 16 with the goal of reducing postoperative complications. The most common treatable cause of perioperative anemia is iron deficiency, which may result from either acute/chronic blood loss, cancer, nutritional deficiency (which can also cause other hematinic deficiencies such as folate, B12, zinc, copper, etc.…”

Section: Introductionmentioning

confidence: 99%

“… 16 , 19 , 20 Although, therapy with iron improves preoperative hemoglobin levels, there is controversial evidence about whether preoperative anemia optimization decreases major postoperative complications and mortality. 4 , 11 , 12 , 13 , 14 , 15 , 21 , 22 , 23 , 24 , 25 , 26 Large retrospective studies found that intravenous iron contributes to the reduction of morbidity and mortality, length of stay and nosocomial infections in patients having major procedures. 14 , 24 However, when preoperative anemia optimization was tested in prospective trials in patients undergoing major elective surgery 22 and abdominal surgeries 15 , 26 , 27 and even in metanalysis, 28 , 29 no difference on postoperative complications, or mortality was found.…”

Section: Introductionmentioning

confidence: 99%